Groningen, Netherlands – 2 January 2025 – InnoCore Pharmaceuticals (InnoCore), a leading drug delivery development provider of Long Acting Injectable (LAI) dosage forms, has launched its new business strategy based on its proprietary best-in-class polymeric drug delivery platform, SynBiosys®.
The unique properties of the SynBiosys® platform for complex active pharmaceutical ingredients (APIs) underlie the Management’s decision to focus InnoCore’s business development activities on growing its share of the Biologics and Peptide formulation market.
InnoCore is an established industry player in the formulation and manufacture of LAI dosage forms. With a 20+ year track record, the company regularly works with some of the world’s largest pharma companies as well as renowned biotech companies and research institutions.
Sustained release LAIs of biologics and peptides are in growing demand for use in chronic diseases, markets worth multi billion dollars. These molecules’ inherent specificity and potency make them powerful therapeutic candidates across numerous clinical areas, including endocrinology, immunology, and oncology. However, their structural fragility and susceptibility to enzymatic breakdown presents significant challenges with respect to formulation, manufacture, scale-up and administration especially in the field of long acting formulations.
InnoCore’s SynBiosys® drug delivery platform provides a sophisticated solution to these challenges. SynBiosys® can overcome the significant technical challenges of translating complex and fragile APIs into stable, tunable and scalable LAI drug products whilst maintaining the essential bioactive characteristics of the API.
Robert Hof, CEO, said:
“SynBiosys® offers unique features across all stages of drug candidate formulation and development. Its matrix safeguards peptides and biologics from aggregation, enzymatic degradation, and acylation, thereby protecting the structural integrity of these complex molecules and preserving their bioactivity. SynBiosys® best-in-class properties also create important strategic competitive differentiation opportunities. The pivot of the InnoCore strategy towards these innovative modalities and our premium service can help to significantly strengthen and differentiate the product portfolio of our customers.”
SynBiosys® is a biodegradable polymer matrix platform capable of encapsulating peptides, as well as larger proteins and small molecules, in various dosage forms such as microspheres, implants or in-situ forming depots. Upon exposure to an aqueous environment, the polymer swells and gradually releases the peptide via a combination of diffusion and bioerosion, delivering a controlled, linear release tailored from several days up to several months.
-Ends-
For more information, please contact:
Notes to Editors
About InnoCore Pharmaceuticals
InnoCore Pharmaceuticals is a leading drug delivery development provider, formulating peptide and biologic APIs into scalable, and tunable Long Acting Injectable (LAI) dosage forms.
The Company’s proprietary polymeric drug delivery platform, SynBiosys®, overcomes the significant technical challenges of translating these complex and fragile molecules into LAI drug products that maintain their essential bioactive characteristics.
Dosage forms can be created for early proof of concept, through to clinical trial usage in an easy-to-scale cGMP form. These formulations can be adapted for use in local or systematic injectable forms for a wide range of therapeutic applications, such as osteoarthritis, rheumatology, oncology, CNS, infectious and cardiometabolic diseases.
InnoCore is a true strategic partner to its biopharma customers working hand-in-hand with them to lay strong foundations for future clinical and commercial success. InnoCore is innovating biologic drug formulation for better treatment outcomes and compliance.
For more information, please see: www.innocorepharma.com.